Isolated-FAMSD¥Ä¡¼¥ë

¥Ð¥¤¥ª¥¤¥ó¥Õ¥©¥Þ¥Æ¥£¥¯¥¹ µ»½Ñ¤òÍѤ¤¤¿¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¥Ä¡¼¥ë¤È¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥â¥Ç¥ë¤Ë´Þ¤Þ¤ì¤ë¥ê¥¬¥ó¥É¤ò¥Æ¥ó¥×¥ì¡¼¥È¤ËÍѤ¤¤¿¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°¥Ä¡¼¥ë¤òÈ÷¤¨¤¿¥É¥Ã¥­¥ó¥°¥·¥ß¥å¥ì¡¼¥·¥ç¥ó¥Ä¡¼¥ë¤Ç¤¹

ËÌΤÂç³ØÌô³ØÉôÇß»³¸¦µæ¼¼¤Ç³«È¯¤·¤¿¥¿¥ó¥Ñ¥¯¼Á¥â¥Ç¥ê¥ó¥°µ»½Ñ(PDFAMS¥×¥í¥°¥é¥à)¡¢¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤É¾²Áµ»½Ñ(Circle¥×¥í¥°¥é¥à)¡¢¥Ð¥¤¥ª¥¤¥ó¥Õ¥©¥Þ¥Æ¥£¥¯¥¹¾ðÊó¤òÍøÍѤ·¤¿¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°µ»½Ñ(ChooseLD¥×¥í¥°¥é¥à)¤Ê¤É¤ò£±Âæ¤Î Linux PC(10Ëü±ßÄøÅÙ) ¤ËÁȤ߹þ¤ó¤À Isolated-FAMSD ¥·¥¹¥Æ¥à¤ò¤Ä¤¯¤ê¾å¤²¤Þ¤·¤¿¡£
¥¢¥ß¥Î»ÀÇÛÎó¤ò Isolated-FAMSD ¤Î Web Browser ¤ËÆþÎϤ¹¤ë¤³¤È¤Ë¤è¤ê¡¢¼ï¡¹¤Î¥¢¥é¥¤¥á¥ó¥È·×»»·ë²Ì¤¬ Web ¾å¤Ëɽ¼¨¤µ¤ì¤Þ¤¹¡£¤½¤ì¤é·ë²Ì¤ÎÃ椫¤éÃò·¿¥¿¥ó¥Ñ¥¯¼Á¤ò¡¢É¬Íפʤé¤Ð Ligand ʬ»Ò¤â´Þ¤á¤Æ Web ¾å¤ÇÁªÂò¤·¤Æ Target ¥¿¥ó¥Ñ¥¯¼Á¤ò¥â¥Ç¥ê¥ó¥°¤Ç¤­¤Þ¤¹¡£Ã±¿ôº¿(ñÂÎ)¥¿¥ó¥Ñ¥¯¼Á¤À¤±¤Ç¤Ê¤¯¡¢Ê£¹çÂÎ(½Å¹çÂÎ)¥¿¥ó¥Ñ¥¯¼Á¤â¥â¥Ç¥ê¥ó¥°²Äǽ¤Ë¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£¤½¤ÎºÝ¡¢Ãò·¿¥¿¥ó¥Ñ¥¯¼Á°Ê³°¤Ë´Þ¤Þ¤ì¤ë¥ê¥¬¥ó¥É¤â¡¢Ãò·¿¥¿¥ó¥Ñ¥¯¼Á¤ÎºÂɸ·Ï¤Ë¹ç¤ï¤»¤Æ´Þ¤á¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£
¤µ¤é¤Ë¤½¤ì¤é¥ê¥¬¥ó¥É¤ò´Þ¤à¥¿¥ó¥Ñ¥¯¼Á¥â¥Ç¥ë¤Î¥ê¥¬¥ó¥É¤ò FingerPrint(²½¹çʪ»ØÌæ)¤Ë»ØÄꤷ¤Æ¡¢¥ê¥¬¥ó¥É·²¤Î¸¶»Ò¥¿¥¤¥×¤ä¸¶»Ò¥¿¥¤¥×·ë¹ç¤¬ FingerPrint ¤Î¤½¤ì¤é¤Ë¥Õ¥£¥Ã¥È¤¹¤ë¤è¤¦¤Ë²½¹çʪ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Ê¤É¤Î¸õÊä²½¹çʪ¤Î¥Õ¥ê¡¼¤Ê·ë¹ç¤ò²óž¤µ¤»¤Ê¤¬¤é¥â¥ó¥Æ¥«¥ë¥í¼êË¡¤òÍøÍѤ·¤Æ¥É¥Ã¥­¥ó¥°¤·¤¿ºÇŬ¤Ê²½¹çʪ¡Ý¼õÍÆÂÎ¥¿¥ó¥Ñ¥¯Ê£¹çÂΤòÆÀ¤ë chooseLD ¼êË¡¤â´Þ¤Þ¤ì¤Æ¤¤¤Þ¤¹¡£
¥¿¥ó¥Ñ¥¯¼Á¥â¥Ç¥ë¤Ë´Þ¤Þ¤ì¤ëÊä·çʬ»Ò(Êä¹ÚÁǤʤÉ)¤Î¥ê¥¬¥ó¥É¤Ï¡¢Mediator ÀßÄꤹ¤ë¤³¤È¤Ë¤è¤ê¡¢¥É¥Ã¥­¥ó¥°¶õ´Ö¤«¤é½ü¤¯¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£
chooseLD ¤Ç¤Ï¡¢¥Û¥â¥í¥¸¡¼¥â¥Ç¥ê¥ó¥°¤ÇºîÀ½¤·¤¿ Target ¥¿¥ó¥Ñ¥¯¼Á¤Î³èÀ­Éô°Ì(FingerPrint)¶õ´Ö¤Ë¥Æ¥¹¥È²½¹çʪ¤ò¥É¥Ã¥­¥ó¥°¤µ¤»¤ë¤Î¤Ç¡¢¥¿¥ó¥Ñ¥¯¼Á¤Î³èÀ­È¯´ø¶õ´Ö¤Ë¥Õ¥£¥Ã¥È¤·¤¿¼õÍÆÂΡ¼¥Æ¥¹¥È²½¹çʪʣ¹çÂι½Â¤¤¬ÆÀ¤é¤ì¤ë¤Î¤¬ÆÃħ¤Ç¤¹¡£

Ëܥġ¼¥ë¤Ë¤´´Ø¿´¤¬¤¢¤ê¤Þ¤¹Êý¤Ï¡¢¤ªÌ䤤¹ç¤ï¤»¥Õ¥©-¥à¤«¤é¤ª´ê¤¤¤¤¤¿¤·¤Þ¤¹¡£

Circle¡§¥¿¥ó¥Ñ¥¯¼Áͽ¬¥â¥Ç¥ë¤ò Free Energy ¥é¥¤¥¯¤Î´Ø¿ô¤Çɾ²Á¤·¤Æ¤¤¤Þ¤¹¡£
Proteins, 69, Suppl 8, 98-107 (2007)
JP ÆôêÈÖ¹æÂè4643713¹æ(2010ǯ12·î10ÆüÅÐÏ¿)
chooseLD¡§
Chem Pharm Bull (Tokyo)., 56(5), 742-744 (2008).
JP ÆõöÈÖ¹æÂè4564097¹æ(2010ǯ8·î6ÆüÅÐÏ¿)


Circle¥Ä-¥ë

PDFAMS¤Ë¤è¤ëÊ£¿ô¤Î¥â¥Ç¥ë¤«¤é¤ÎºÇÎÉ¥â¥Ç¥ë¼«Æ°È½ÊÌ¥Ä-¥ë

2006ǯ²Æ¤Ë³«ºÅ¤µ¤ì¤¿¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¤Î¹ñºÝ¥³¥ó¥Æ¥¹¥ÈCASP7(Critical Assessment of Techniques for Protein Structure Prediction)¤Ë¤ª¤¤¤Æ¡¢³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÇß»³¶µ¼ø¤Ï¡¢200¤òĶ¤¨¤ë»²²Ã¥°¥ë¡¼¥×¤ÎÃæ¤ÇÀ¤³¦ºÇ¹â¥ì¥Ù¥ë¤ÎÀ®ÀÓ¤ò¤ª¤µ¤á¤Þ¤·¤¿¡£
CASP7¤Ç¿¿ô¤Î¥â¥Ç¥ë¤«¤éºÇŬ¤Ê¥â¥Ç¥ë¤òÁª¤Ó½Ð¤·¡¢Ãø¤·¤¯¥â¥Ç¥ë¤ÎÀºÅÙ¤ò¸þ¾å¤µ¤»¤ë¤³¤È¤ËÀ®¸ù¤·¤¿¥¯¥¦¥©¥ê¥Æ¥£¡¼¥¢¥»¥¹¥á¥ó¥È¥×¥í¥°¥é¥à(CIRCLE)¤òPDFAMS¤ËÁȹþ¤ß¤Þ¤·¤¿¡£
PDFAMS¤ÈƱÍͤËFASTA·Á¼°¤Ç¥¢¥ß¥Î»ÀÇÛÎó¤òÆþÎϤ¹¤ë¤È¡¢³Æ¼ï¥¢¥é¥¤¥á¥ó¥È¥Ä¡¼¥ë(PDFAMS¤Ç¤ÏPDB 95% NR¤ËÂФ¹¤ëRPS-BLAST¤À¤±¤Ç¤¹¤¬¡¢PDB 95% NR¡¢Pfam¡¢NCBI NR¤Ê¤É¤Î¥Ç-¥¿¥Ù-¥¹¤ËFASTA¡¢BLAST¡¢PSI-BLAST¡¢IMPALA¡¢PSI-PRED¤òÁȤ߹ç¤ï¤»¤Æ¼Â¹Ô)¤«¤éÆÀ¤é¤ì¤ë¥¢¥é¥¤¥á¥ó¥È¥Ç-¥¿¤ÎÃ椫¤é¡¢PDFAMS¤ÇÍ­°Õ¤Ê¿ô¤À¤±¥â¥Ç¥ê¥ó¥°¤ò¤·¤¿¤Î¤Á¡¢CIRCLE¤Ç¤½¤ì¤é¥â¥Ç¥ë¤Î½ç°ÌÉÕ¤±¤ò¤Ë¹Ô¤¤¡¢ºÇÎɤΥâ¥Ç¥ë¹½Â¤¤¬¤É¤ì¤«¤òõ¤·¤À¤¹µ¡Ç½¤òÍ­¤¹¤ë¥Ä-¥ë¤Ç¤¹¡£

ËÜ¥Ä-¥ë¤Ë¤´´Ø¿´¤¬¤¢¤ê¤Þ¤¹Êý¤Ï¡¢¤ªÌ䤤¹ç¤ï¤»¥Õ¥©-¥à¤«¤é¤ª´ê¤¤¤¤¤¿¤·¤Þ¤¹¡£

CASP7¤Î·ë²Ì¡¢CIECLE¤Î¾ÜºÙ:
Proteins, 69, Suppl 8, 98-107 (2007)
JP ÆôêÈÖ¹æÂè4643713¹æ(2010ǯ12·î10ÆüÅÐÏ¿)
>

ProteinDiscovery¤Î¤´¾Ò²ð

-¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬µ»½Ñ¤ò´ðÈפË-

ÁÏÌô¤ò¹Ô¤¦¤Ë¤¢¤¿¤ê¡¢¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤òÃΤ뤳¤È¤ÏɬÍ×ÉԲķç¤Ç¤¹¡£ ¤·¤«¤·¡¢°ìÈ̤˥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤òÀºÅÙÎɤ¯µá¤á¤ë¤³¤È¤ÏÈó¾ï¤Ëº¤Æñ¤Ç¡¢ ¤«¤Ä½ÏÎý¤òÍפ¹¤ëºî¶È¤È¤Ê¤ê¤Þ¤¹¡£
ÊÀ¼Ò¤Ç¤ÏËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤òÃæ¿´¤ËÇݤï¤ì¤¿´ðÈ×µ»½Ñ¤ò³è¤«¤·¤¿ ProteinDiscoveryÀ½ÉÊ·²¤Î³«È¯¡¦ÈÎÇ䡦¥µ¥Ý¡¼¥È¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£ ¤½¤ÎÃæ³Ë¤òô¤¦¤Î¤¬¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Í½Â¬¥Ä¡¼¥ëPDFAMS¥·¥ê¡¼¥º ¥½¥Õ¥È¥¦¥§¥¢¤Ç¤¢¤ê¡¢ ÍÍ¡¹¤Ê¥ª¥×¥·¥ç¥ó¥â¥¸¥å¡¼¥ë¤òÄɲ乤뤳¤È¤Ç ¿ºÌ¤Êµ¡Ç½¤äÀ¤³¦¥È¥Ã¥×¥ì¥Ù¥ë¤Îͽ¬ÀºÅÙ¤ò¼Â¸½¤¹¤ë¤³¤È¤¬²Äǽ¤Ç¤¹¡£ ¤½¤ÎÀ®²Ì¤Î°ìü¤È¤·¤Æ¡¢¿··¿ÇÙ±ê¤Ç¤¢¤ë½Å¾ÉµÞÀ­¸ÆµÛ´ï¾É¸õ·²SARS¤Î¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¤òͽ¬¤¹¤ë¤³¤È¤ËÀ®¸ù¤·¡¢À¤³¦¤ËÀè¶î¤±¤Æ¥â¥Ç¥ë¹½Â¤¤ò¸ø³«¤·¤Æ¤¤¤Þ¤¹¡£
Rep
PDFAMS¥·¥ê¡¼¥º ¥½¥Õ¥È¥¦¥§¥¢¤Ë¤è¤êͽ¬¤µ¤ì¤¿SARS¥¦¥£¥ë¥¹¤ÎRNA PolymeraseΩÂι½Â¤
¤¿¤À¤¤¤ÞSARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤¤ò̵½þÄó¶¡Ã桪

¿·Ãå¾ðÊó

2014ǯ4·î5Æü £´·î£±ÆüÉդǵ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤Ç¤¢¤ëÇß»³½¨ÌÀËÌΤÂç³Ø̾ÍÀ¶µ¼ø¤¬¡¢Ãæ±ûÂç³Ø2014ǯÅÙÂç³Ø±¡Íý¹©³Ø¸¦µæ²Ê·óǤ¹Ö»Õ¤Ë½¢Ç¤¤·¤Þ¤·¤¿¡£new
2014ǯ3·î1Æü ¥¢¥¸¥¢ÂÀÊ¿ÍΥХ¤¥ª¥¤¥ó¥Õ¥©¥Þ¥Æ¥£¥¯¥¹¥«¥ó¥Õ¥¡¥ì¥ó¥¹³Ø²ñ(APBC 2014¡¢¾å³¤)¤Ç¡¢¡Ö٨ʿ¾åÈé´â¤Ë¤ª¤±¤ë°äÅÁ»ÒÆðÛŪDNA¤Î¥á¥Á¥ë²½¤Ë´ØÏ¢¤¹¤ëÌôʪɸŪ¸õÊä¤Ë¤Ê¤ê¤¦¤ë¥²¥Î¥à¡×¤Î±éÂê¤Çȯɽ¤·¤Þ¤·¤¿¡£new
2013ǯ12·î10Æü CASP10ɾ²Á¥ß¡¼¥Æ¥£¥ó¥°(Gaeta(Italy) on December 9-12, 2012)¤Ë¤ª¤¤¤Æ¡¢Íâǯ 2013 ǯ¤Î¥Î¡¼¥Ù¥ë²½³Ø¾Þ¤ò Martin Karplus ¤È Arieh Warchel ¤ÎÆó¿Í¤È¶¦Æ±¼õ¾Þ¤·¤¿ Michael Levitt ¤¬¡¢ÆÃÊֱ̹é¤ò¹Ô¤Ã¤¿¤È¤­¤ÎºÂŤòµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤Ç¤¢¤ëÇß»³½¨ÌÀËÌΤÂç³Ø̾ÍÀ¶µ¼ø¤¬Ì³¤á¤Þ¤·¤¿¡£
2013ǯ12·î1Æü ³ô¼°²ñ¼Ò¥ä¥¯¥ë¥ÈËܼҤȤÎÁÏÌô¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤Î¶¦Æ±¸¦µæÀ®²Ì¡¢¡ØPlk-1Á˳²ºÞ¡ÙÆôê2008-80329(2008ǯ3·î26Æü½Ð´ê) ÆõöÂè5405760¹æ (2013ǯ11·î8ÆüÅÐÏ¿)¡¢¤Ê¤é¤Ó¤Ë¡¢¡ØMMPÁ˳²ºÞ¡ÙÆôê2010-502734(2009ǯ3·î13Æü½Ð´ê) ÆõöÂè5421238¹æ 2013ǯ11·î29ÆüÅÐÏ¿)¤¬¡¢Æõö¸¢²½¤µ¤ì¤Þ¤·¤¿¡£
2013ǯ10·î1Æü ¡Ö¥¢¥ß¥Î»ÀÊѰۤ˴ð¤Å¤¯¥¿¥ó¥Ñ¥¯¼Á¡¼¥¿¥ó¥Ñ¥¯¼ÁÁê¸ßºîÍѤÎÊѲ½Í½Â¬(CAPRI)¡×¤Ë»²²Ã¤·¤¿¥°¥ë¡¼¥×¤ÎΩÂι½Â¤Í½Â¬É¾²Á¤ÎÏÀʸ¤Ë¤ï¤ì¤ï¤ì¤Î¼êË¡¤¬ºÜ¤Ã¤Æ¤¤¤Þ¤¹¡£
2013ǯ8·î1Æü ¡Ö¼«¸ÊÌȱּÀ´µ°äÅÁ»Ò¤Ë´ð¤Å¤¯FAMS¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥â¥Ç¥ë¤òÍѤ¤¤¿¼«¸ÊÌȱּÀ´µÌôʪ³«È¯¤Î¤¿¤á¤Î¥Ð¥¤¥ª¥¤¥ó¥Õ¥©¥Þ¥Æ¥£¥¯¥¹µ»½Ñ¤ò»È¤Ã¤¿¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°¡×¤ÎÏÀʸ¤¬¸øɽ¤µ¤ì¤Þ¤·¤¿¡£
2012ǯ7·î26Æü RIKEN FAMSBASE¤¬Ãæ±ûÂç³ØÍý¹©³ØÉôÀ¸Ì¿²Ê³Ø²Ê¤Î´ä´ÜËþͺ½Ú¶µ¼ø¤ÈÇß»³½¨ÌÀ¶¦Æ±¸¦µæ°÷(ËÌΤÂç³Ø̾ÍÀ¶µ¼ø)¤Ë¤è¤êÃæ±ûÂç³Ø¤Î¥µ¥¤¥È¤«¤éºÆ¸ø³«¤µ¤ì¤Þ¤·¤¿¡£RIKEN FAMSBASE¤ÎËܺƸø³«¤Ï¡¢Íý²½³Ø¸¦µæ½ê¡¢³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¡¢Ãæ±ûÂç³Ø¡¢»°¼Ô´Ö¤Î·ÀÌó¤Ë´ð¤Å¤¯¤â¤Î¤Ç¤¹¡£
2012ǯ7·î26Æü Ʊ»þ¤Ë¡¢GPCRΩÂι½Â¤¥â¥Ç¥ë¥Ç¡¼¥¿¥Ù¡¼¥¹¤¬Ãæ±ûÂç³ØÍý¹©³ØÉôÀ¸Ì¿²Ê³Ø²Ê¤Î´ä´ÜËþͺ½Ú¶µ¼ø¤ÈÇß»³½¨ÌÀ¶¦Æ±¸¦µæ°÷(ËÌΤÂç³Ø̾ÍÀ¶µ¼ø)¤Ë¤è¤êÃæ±ûÂç³Ø¤Î¥µ¥¤¥È¤«¤é¸ø³«¤µ¤ì¤Þ¤·¤¿¡£
2011ǯ1·î20Æü CASP9¤Îɾ²Á¥ß¡¼¥Æ¥£¥ó¥°¤Ç¤Î Free Modeling (FM) ÉôÌç¤Î¥¢¥»¥Ã¥µ¡¼¤¬»È¤Ã¤¿É¾²Á¥¹¥é¥¤¥É¤¬¸ø³«¤µ¤ì¤Þ¤·¤¿¡£FAMS-ACE(37)¥°¥ë¡¼¥×¤ÏÀ¤³¦Â裶°Ì¡¢SPLICER(88)¤ÏÂ裷°Ì¡¢FAMSSEC(113)¤ÏÂ裹°Ì¤Ç¤¢¤ë¤³¤È¤¬¤ï¤«¤ê¤Þ¤¹¡£(¥¹¥é¥¤¥É155ËçÌܤÎComS¥é¥ó¥¯,159,160ËçÌÜ»²¾È)
2011ǯ1·î19Æü CASP9¤Îɾ²Á¥ß¡¼¥Æ¥£¥ó¥°¤Ç¤Î Ligand Binding Site Prediction (FN) ÉôÌç¤Î¥¢¥»¥Ã¥µ¡¼¤¬»È¤Ã¤¿É¾²Á¥¹¥é¥¤¥É¤¬¸ø³«¤µ¤ì¤Þ¤·¤¿¡£FAMSSEC¥°¥ë¡¼¥×(FN113)¤ÏÀ¤³¦Â裴°Ì(1,2°Ì¤¬Æ±¤¸¥°¥ë¡¼¥×¤Ê¤Î¤Ç¼Â¼ÁÀ¤³¦Âè3°Ì)¤Ë¤Ê¤ê¤Þ¤¹¡£(¥¹¥é¥¤¥É12ËçÌܤÎMCC Score¡¢14ËçÌܤÎMCC Z-score¤Ë¤è¤ëξɾ²Á¤È¤â)
2011ǯ1·î4Æü Æôê2008-545463¡Ø¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤½èÍýÁõÃÖ¡¢¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤½èÍýÊýË¡¡¢¤ª¤è¤Ó¡¢¥×¥í¥°¥é¥à¡Ù¤ÎÆõö¾É (Æõö4643713¹æ 2010ǯ12·î10Æü) ¤ò¼õÎΤ·¤Þ¤·¤¿¡£
2010ǯ12·î25Æü ¥¿¥ó¥Ñ¥¯¼Á¤Î¹½Â¤¥¯¥¦¥©¥ê¥Æ¥£¡¼¥¢¥»¥¹¥á¥ó¥È¥×¥í¥°¥é¥à(Circle)¤Ë´Ø¤¹¤ëÃø½ñ(ʬô¼¹É®)¤¬Jone Wiley & Sons Inc.¤«¤é½ÐÈǤµ¤ì¤Þ¤·¤¿¡£"Introduction to Protein Structure Prediction: Methods and Algorithms", Edited by Huzefa Rangwala and George Karypis, Jone Wiley & Sons, Inc. (2010) ISBN 978-0-470-47059-6 CHAPTER 14, pp299-321 Model Quality Assessment Using a Statistical Program that Adopts a Side Chain Environment Viewpoint (Genki Terashi, Mayuko Takeda-Shitaka, Kazuhiko Kanou, Hideaki Umeyama)
2010ǯ12·î21Æü CASP9(5·î¡Á7·î¤Ë129Ìä¤Î¥¢¥ß¥Î»ÀÇÛÎó¤ËÂФ·¤Æ¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤òͽ¬¤·¡¢±£¤µ¤ì¤¿²òÅú¤Ë´ð¤Å¤­½ç°Ì¤ò¶¥¤¦¥³¥ó¥Æ¥¹¥È)¤Îɾ²Á¥ß¡¼¥Æ¥£¥ó¥°¤¬12·î5Æü¤«¤é9Æü¤Þ¤ÇCalifornia Monterey¶á¤¯¤ÎAsilomar Conference Center¤Ç³«¤«¤ì¤Þ¤·¤¿¡£¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤¬Ãæ¿´¤È¤Ê¤Ã¤Æ»²²Ã¤·¤¿FN (Function Prediction (Prediction of Ligand Binding Site)¤ÎÉôÌç(FN113)¤ÇÀ¤³¦Âè4°Ì(1,2°Ì¤¬Æ±¤¸¥°¥ë¡¼¥×¤Ê¤Î¤Ç¼Â¼ÁÀ¤³¦Âè3°Ì)¤Îɾ²Á¤òÆÀ¤ë¤³¤È¤¬¤Ç¤­¤Þ¤·¤¿¡£¤Þ¤¿FNÉôÌç¤ÎÍ¥½¨¤ÊÀ®ÀӤˤè¤êÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¡¼¥¶¡¼¤ÎÇß»³½¨ÌÀËÌΤÂç³Ø̾ÍÀ¶µ¼ø¤¬¥Ñ¥Í¥ê¥¹¥È¤È¤·¤Æ¾·ÂÔ¤µ¤ì¹Ö±é¤·¤Þ¤·¤¿¡£
2010ǯ12·î21Æü Çß»³¥°¥ë¡¼¥×¤ÎFAMS¤òÍѤ¤¤¿CASP9¤ÎÃò·¿¥¿¥ó¥Ñ¥¯¼Á¥â¥Ç¥ê¥ó¥°(TMB)¥«¥Æ¥´¥ê¡¼¤ÎÀ®ÀӤϡ¢FAMS SEC¤ÏÀ¤³¦Âè6°Ì¡¢FAMS multi¤ÏÂè7°Ì¡¢FAMS ACE3¤ÏÂè10°Ì¤ÇÀ¤³¦¤Î10°Ì°ÊÆâ¤Ë3¥°¥ë¡¼¥×¤¬Æþ¤Ã¤Æ¤¤¤ë²÷µó¤òÀ®¤·¿ë¤²¤Þ¤·¤¿¡£Free Modeling(FM)ÉôÌç¤Ç¤â¥Ñ¥Í¥ê¥¹¥È¤È¤·¤Æ¾·ÂÔ¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
2010ǯ11·î27Æü Æôê2008-545463 ¡Ø¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤½èÍýÁõÃÖ¡¢¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤½èÍýÊýË¡¡¢¤ª¤è¤Ó¡¢¥×¥í¥°¥é¥à¡Ù(Ä̾ÎCircle) ¤ÎÆõöººÄ꤬ʿÀ®22ǯ11·î15ÆüÉդǤª¤ê¤Þ¤·¤¿¡£
2010ǯ11·î10Æü Âè38²ñ¹½Â¤³èÀ­Áê´Ø¥·¥ó¥Ý¥¸¥¦¥à(10·î30Æü(ÅÚ)¡Á31Æü(Æü) ÆÁÅçÂç³Ø¹©³ØÉô)¤ÎÆÃÊÌ¥»¥Ã¥·¥ç¥ó¡Ö¥¿¥ó¥Ñ¥¯¼Á¥Û¥â¥í¥¸¡¼¥â¥Ç¥ê¥ó¥°¤È¹½Â¤³èÀ­Áê´Ø¤ÎÍ»¹ç¡×¤Ë¤ª¤¤¤Æ¡¢ÊÀ¼Ò¤ÎPDFAMS¤òÍѤ¤¤¿¸¦µæÀ®²Ì¤Î¹Ö±é¤¬ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀËÌΤÂç³Ø̾ÍÀ¶µ¼ø¤ÈµþÅÔÂç³ØÂç³Ø±¡ÇÀ³Ø¸¦µæ²Ê¤ÎÆó¿Í¤ÎÍ­Îϥ桼¥¶¤«¤é¤¢¤ê¤Þ¤·¤¿¡£Çß»³Ì¾ÍÀ¶µ¼ø¤Ï¡¢¥ê¥¬¥ó¥É¤ò´Þ¤àÊ£¹çÂÎ¥¿¥ó¥Ñ¥¯¼Á¤Î¥â¥Ç¥ê¥ó¥°¤«¤é¡¢¤½¤ì¤éΩÂι½Â¤¤òÍѤ¤¤¿ChooseLD¤Ë¤è¤ë¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤ò¡¢°ìÂæ¤ÎLinux PC¤ÎWeb Browser¾å¤Ç¹Ô¤¨¤ë¤³¤È¤ò¹Ö±é¤·¤Þ¤·¤¿¡£(¥¹¥é¥¤¥É¸¶¹Æ¤Î¥À¥¦¥ó¥í¡¼¥É)
2010ǯ9·î18Æü NDM-1(¥Ë¥å¡¼¥Ç¥ê¡¼¡¦¥á¥¿¥í-¦Â-¥é¥¯¥¿¥Þ¡¼¥¼)»ºÀ¸¶Ý¤È¸Æ¤Ð¤ì¤ë¡¢¤Û¤È¤ó¤É¤Î¹³À¸Êª¼Á¤¬¸ú¤«¤Ê¤¤¿··¿Â¿ºÞ¶Ý¤Î¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤ò¡¢ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀËÌΤÂç³Ø̾ÍÀ¶µ¼ø¤¬¥¹¥¿¥ó¥É¥¢¥í¥ó·¿¤ÎLinux PC¤Ç¥â¥Ç¥ê¥ó¥°¤·¡¢Íý²½³Ø¸¦µæ½ê¤ÎWeb¥µ¥¤¥È¤«¤é¸ø³«¤·¤¿¤³¤È¤¬¡¢ÆüËܷкѿ·Ê¹£¹·î17ÆüÄ«´©38Ì̤˺ܤê¤Þ¤·¤¿¡£
2010ǯ8·î23Æü Æôê2009-521050¡Ø¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê> ¡¼¥Ë¥ó¥°ÁõÃÖ¡¢¤ª¤è¤Ó¡¢¥¤¥ó¥¹¥¯¥ê¡¼¥Ë¥ó¥°ÊýË¡¡Ù¤ÎÆõö¾É (Æõö4564097¹æ 2010ǯ8·î6Æü) ¤ò¼õÎΤ·¤Þ¤·¤¿¡£
2010ǯ7·î28Æü Æôê2009-521050¡Ø¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°ÁõÃÖ¡¢¤ª¤è¤Ó¡¢¥¤¥ó¥¹¥¯¥ê¡¼¥Ë¥ó¥°ÊýË¡¡Ù¤ÎÆõöººÄ꤬ʿÀ®22ǯ7·î21ÆüÉդǤª¤ê¤Þ¤·¤¿¡£
2010ǯ4·î1Æü ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤¬3·î31Æü¤ËÄêǯÂà´±¤·¡¢4·î1ÆüÉÕ¤±¤ÇËÌΤÂç³Ø̾ÍÀ¶µ¼ø¤Î¾Î¹æ¤ò¼øÍ¿¤µ¤ì¤Þ¤·¤¿¡£
2010ǯ4·î1Æü ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉô£Á½Ú¶µ¼ø(Ëܿͤδõ˾¤Ë¤è¤êƿ̾µ­½Ò)¤¬¡¢4·î1ÆüÉÕ¤±¤Ç¶µ¼ø¤Ë¾ºÇ¤¤·¤Þ¤·¤¿¡£
2009ǯ11·î27Æü ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤¬³Ø²ñ¡¢ÏÀʸÅù¤Ëȯɽ¤·¤¿¶ÈÀÓ¤ò¹¹¿·¤·¤Þ¤·¤¿¡£
2009ǯ11·î2Æü ³ô¼°²ñ¼Ò¥ä¥¯¥ë¥ÈËܼҤȤÎÁÏÌô¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤Î¶¦Æ±¸¦µæÀ®²Ì¤¬Æõö¸ø³«¤µ¤ì¤Þ¤·¤¿¡£¡ØPlk-1Á˳²ºÞ¡ÙÆôê2008-80329(2008ǯ3·î26Æü½Ð´ê)¡¢Æó«2009-234949(2009ǯ10·î15Æü¸ø³«)
2009ǯ10·î2Æü ³ô¼°²ñ¼Ò¥ä¥¯¥ë¥ÈËܼҤȤÎÁÏÌô¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤Î¶¦Æ±¸¦µæÀ®²Ì¤¬Æõö¸ø³«¤µ¤ì¤Þ¤·¤¿¡£¡ØMMPÁ˳²ºÞ¡ÙPCT/JP2009/001147(2009ǯ3·î13Æü½Ð´ê)¡¢WO/2009/113320(2009ǯ9·î17Æü¸ø³«)
2009ǯ9·î9Æü µþÅÔÂç³ØÂç³Ø±¡ÇÀ³Ø¸¦µæ²ÊÀÖ¾¾Èþµª½Ú¶µ¼ø¤ÎPDFAMS¤òÍѤ¤¤¿¥â¥Ç¥ê¥ó¥°¤ò¹Ô¤Ã¤¿ÏÀʸ¤¬¡¢Molecular Pharmacology 76 (1), 1-10 (2009)¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£¤½¤ÎÃæ¤ÎFigure 8¤¬ÏÀʸ»¨»ï¤Îɽ»æ¤ò¾þ¤Ã¤Æ¤¤¤Þ¤¹¡£
2009ǯ8·î21Æü ¹ñÆâ½Ð´ê¤ÎLigand FAMSµ¡Ç½¡Ø¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Í½Â¬ÁõÃÖ¡¢¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Í½Â¬ÊýË¡¡¢¥×¥í¥°¥é¥à¤ª¤è¤Óµ­Ï¿ÇÞÂΡ٤¬ÆõöººÄꤵ¤ì¤Þ¤·¤¿¡£
2009ǯ8·î20Æü ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤¬³Ø²ñ¡¢ÏÀʸÅù¤Ëȯɽ¤·¤¿¶ÈÀÓ¤ò¥ê¥¹¥È¥¢¥Ã¥×¤·¤Þ¤·¤¿¡£
2009ǯ6·î18Æü CASP8¤Ë¤ª¤±¤ëFAMS¥°¥ë¡¼¥×¤Î¹¥À®ÀӤˤè¤ê¡¢¾å°Ì5¥Á¡¼¥à¤Ë¤è¤ëROUND TABLE¤ÇÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼Çß»³½¨ÌÀËÌΤÂç³ØÌô³ØÉô¶µ¼ø¤¬¥×¥ì¥¼¥ó¥Æ¡Ý¥·¥ç¥ó¡¦¥Ç¥£¥¹¥«¥Ã¥·¥ç¥ó¤ò¹Ô¤¤¤Þ¤·¤¿¡£
2009ǯ6·î17Æü 6·î18Æü(ÌÚ)¤È19Æü(¶â)¤Ë¡¢ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉô£Á½Ú¶µ¼ø(Ëܿͤδõ˾¤Ë¤è¤êƿ̾µ­½Ò)¤ò¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2009¼Â¹Ô°Ñ°÷Ĺ¤È¤·¤Æ¡¢
¹Ö±é²ñ¡Ö¥Û¥â¥í¥¸¡¼¥â¥Ç¥ê¥ó¥°(¥Ê¥ÎÀ¸Ì¿Àß·×)¤ÈÁÏÌô¡×¤Ê¤é¤Ó¤Ë¡Ö¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2009¡Ô²½¹çʪ¤ÈɸŪ¡¦ÈóɸŪ¥¿¥ó¥Ñ¥¯¼Á¤È¤ÎÁê¸ßºîÍÑ -ÁÏÌôɸŪ¤ÎƱÄê¤Èʬ»ÒÀß·×-¡×¤¬ËÌΤÂç³ØÌô³ØÉô¥³¥ó¥Ù¥ó¥·¥ç¥ó¥Û¡¼¥ë¤Ë¤ª¤¤¤Æ¤½¤ì¤¾¤ì³«ºÅ¤µ¤ì¤Þ¤¹¡£ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤â¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2009¼Â¹Ô°Ñ°÷¤Ë¤Ê¤Ã¤Æ¤ª¤ê¤Þ¤¹¡£
2009ǯ6·î10Æü ÆüËܷкѿ·Ê¹6·î6ÆüÄ«´©´ë¶ÈÌÌ(13¥Ú¡¼¥¸)µ»½Ñ¥¦¥©¥Ã¥Á(ÁÏÌô¤ËIT¡¦°äÅÁ»Ò²òÀϳèÍÑ)Íó¤ÎºÇ¸å¤Ë¡¢¥É¥é¥Ã¥°¥Ç¥¶¥¤¥ó¤¬ºÆ¤ÓµÓ¸÷¤òÍá¤Ó¤ëÍýͳ¤È¤·¤Æ¡¢ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼Çß»³½¨ÌÀËÌΤÂç³ØÌô³ØÉô¶µ¼ø¤¬¡Ø(ɵ¤¤Î¸¶°ø¤È¤Ê¤ë)¤¿¤ó¤Ñ¤¯¼Á¤Î£ØÀþ²òÀϤ¬¿Ê¤ß¡¢¥â¥Ç¥ë¹½Â¤¤ÎÀºÅÙ¤â³ÊÃʤ˸þ¾å¤·¤¿¡¢¤³¤³¿ôǯ¤Ç¿®ÍêÅ٤ι⤤À߷פ¬²Äǽ¤Ë¤Ê¤Ã¤¿¡Ù¤³¤È¤¬Â礭¤¤¤È²òÀ⤷¤Æ¤¤¤Þ¤¹¡£
2009ǯ6·î1Æü ¹ñÆâ½Ð´ê¤Î¡ØÊ£¿ôº¿¤òÍ­¤¹¤ë¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¹½ÃÛÊýË¡(Ê£¿ôº¿FAMS)¡Ù¡¢¡Ø¥¿¥ó¥Ñ¥¯¼Á¤Î¥ê¥¬¥ó¥É·ë¹çÉô°Ì¤Î¸¡º÷ÊýË¡¡Ù¡¢¡ØͶƳŬ¹ç¤òÍøÍѤ·¤¿¥ê¥¬¥ó¥Éõº÷ÊýË¡¡Ù¤¬ÆõöººÄꤵ¤ì¤Þ¤·¤¿¡£
2009ǯ5·î22Æü NCBI¤Î¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥£¥ë¥¹´ØÏ¢¥µ¥¤¥È¤¬Íý²½³Ø¸¦µæ½ê¤ÎËÜ¥µ¥¤¥È¤Ë¥ê¥ó¥¯¤òÄ¥¤Ã¤Æ¤¤¤Þ¤¹¡£The result of RPS-BLAST against PDB database, and a summary of amino acid differences in proteins of these viruses are available at Riken National Institute of Japan.
2009ǯ5·î18Æü ÆüËܷкѿ·Ê¹5·î18ÆüÄ«´©²Ê³ØÌÌ(13¥Ú¡¼¥¸)¤Ë¡¢¿··¿¥¤¥ó¥×¥ë¥¨¥ó¥¶¥¦¥£¥ë¥¹¤Ë¤¢¤ë¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¤ò²Ä»ë²½¤¹¤ë¥·¥¹¥Æ¥à¤¬Íý²½³Ø¸¦µæ½ê¤«¤é¸ø³«¤µ¤ì¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£ÊƹñΩÀ¸Êª¹©³Ø¾ðÊ󥻥󥿡¼(NCBI)¤¬¿··¿¥¤¥ó¥Õ¥ë¥¨¥ó¥¶´¶À÷´µ¼Ô¤«¤éºÎ¼è¤·¤¿°äÅÁ»Ò¾ðÊó¤ò´ð¤Ë´¶À÷¤äÁý¿£¤Ë´ØÍ¿¤¹¤ë¥¿¥ó¥Ñ¥¯¼Á¤ò¡¢ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼Çß»³½¨ÌÀËÌΤÂç³ØÌô³ØÉô¶µ¼ø¤¬³«È¯¤·¤¿FAMS¤Ç¥â¥Ç¥ê¥ó¥°¤·¤Æ¤¤¤Þ¤¹¡£
2009ǯ3·î5Æü ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼ËÌΤÂç³ØÌô³ØÉôÇß»³¶µ¼ø¤ÎÊ¿À®21ǯÅÙÆüËÜÌô³Ø²ñ¾Þ¼õ¾Þ¹Ö±é¤Ï¡¢£³·î26Æü(ÌÚ)16:00¡Á17:00¤Ë¹ñΩµþÅÔ¹ñºÝ²ñ´Û1F¥á¥¤¥ó¥Û¡¼¥ë¤Ë¤ª¤¤¤Æ¹Ô¤ï¤ì¤Þ¤¹¡£
2008ǯ11·î28Æü ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤Ï¡Ö¤¿¤ó¤Ñ¤¯¼ÁΩÂι½Â¤¤Î¥Û¥â¥í¥¸¡¼¥â¥Ç¥ê¥ó¥°¸¦µæ¡×¤Ç¡¢Ê¿À®21ǯÅÙÆüËÜÌô³Ø²ñ¾Þ¤ò¼õ¾Þ¤·¤Þ¤·¤¿¡£
2008ǯ6·î23Æü 6·î20Æü(¶â)¤ËËÌΤÂç³ØÌô³ØÉô¥³¥ó¥Ù¥ó¥·¥ç¥ó¥Û¡¼¥ë¤Ë¤ª¤¤¤Æ¡Ö¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2008¡ÔɸŪÃÁÇò¼Á»Ö¸þ¤Î¥±¥ß¥«¥ë¥Ð¥¤¥ª¥í¥¸¡¼¤È¹½Â¤³èÀ­Áê´Ø¡Õ¡×¤¬³«ºÅ¤µ¤ì¡¢ÊÀ¼Òµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¤¬¡Ø¹âǽΨ¥¤¥ó¥·¥ê¥³¥Ñ¥¤¥×¥é¥¤¥ó¸¦µæ¤È¥É¥Ã¥­¥ó¥°°åÌôÉʸôÊä²½¹çʪ¤ÎÁªÂò¡Ù¤Î±éÂê¤Ç¹Ö±é¤·¤Þ¤·¤¿¡£
2008ǯ5·î2Æü ¤ªÌ䤤¹ç¤ï¤»¤ËÂФ¹¤ë¤ªÅú¤¨¡§¤É¤Î¤è¤¦¤Ë¥¢¥ß¥Î»ÀÃÖ´¹¤ò¹Ô¤Ê¤¨¤Ð¡¢¤è¤ê¹â¤¤À¸Íý³èÀ­¤ò¤â¤Ä¥¿¥ó¥Ñ¥¯¼Á¤¬Í½Â¬¤Ç¤­¤½¤¦¤«¡£
2008ǯ4·î26Æü ¥¿¥ó¥Ñ¥¯¼Á¤Î´ð¼ÁÃÖ´¹¤ò£±»Ä´ðÃÖ´¹¤Ë¤è¤Ã¤Æ¹Ô¤Ê¤¦ÊýË¡¤ò³«»Ï¤¤¤¿¤·¤Þ¤·¤¿¡£
2008ǯ4·î26Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤¬½Ð´ê¤·¤Æ¤¤¤ëÆõö¤ò¸ø³«¤¤¤¿¤·¤Þ¤·¤¿¡£
2008ǯ4·î25Æü ¥¿¥ó¥Ñ¥¯¼Á¤Î£±»Ä´ðÃÖ´¹¤ò¼«Í³¥¨¥Í¥ë¥®¡¼¤Î°ÂÄê²½¤ò»Øɸ¤È¤·¤Æ¥ê¥¹¥È¥¢¥Ã¥×¤¹¤ë¥Ó¥¸¥Í¥¹¤ò»Ï¤á¤Þ¤·¤¿¡£Choline dehydrogenase, mitochondrial precursor (CHD)¤òÎã¤Ë¼«Í³¥¨¥Í¥ë¥®¡¼¤Î°ÂÄê¤Ê£±»Ä´ðÃÖ´¹¥¿¥ó¥Ñ¥¯¼Á¤ÎÁÏÀ½¤òͽ¬¤·¤Æ¤¤¤Þ¤¹¡£
2008ǯ4·î23Æü Æôê2002-547051¥¿¥ó¥Ñ¥¯¼Á¤ÎΩÂι½Â¤¹½ÃÛÊýË¡(WO2002/044954 ÆüËܤΤܹ߰Ô)¤¬ÆõöººÄꤵ¤ì¤Þ¤·¤¿¡£
2008ǯ4·î22Æü Ê¿À®20ǯ6·î20Æü(¶â)ËÌΤÂç³ØÌô³ØÉô¥³¥ó¥Ù¥ó¥·¥ç¥ó¥Û¡¼¥ë¤Ç¹½Â¤³èÀ­¥Õ¥©¡¼¥é¥à2008¡ÖɸŪÃÁÇò¼Á»Ö¸þ¤Î¥±¥ß¥«¥ë¥Ð¥¤¥ª¥í¥¸¡¼¤È¹½Â¤³èÀ­Áê´Ø¡×¤¬³«ºÅ¤µ¤ì¤Þ¤¹¡£¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Îµ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀËÌΤÂç³ØÌô³ØÉô¶µ¼ø¤¬¡Ö¹âǽΨ¥¤¥ó¥·¥ê¥³¥Ñ¥¤¥×¥é¥¤¥ó¸¦µæ¤È¥É¥Ã¥­¥ó¥°°åÌôÉʸôÊä²½¹çʪ¤ÎÁªÂò¡×¤Î±éÂê¤Ç¹Ö±é¤·¤Þ¤¹¡£
2008ǯ4·î18Æü Purdue University¤ÎÌÚ¸¶Âç춵¼ø¤é¤¬ºîÀ®¤·¤¿ÂçIJ¶Ý¤Î¥¿¥ó¥Ñ¥¯¼Á¥â¥Ç¥ë¥Ç¡¼¥¿¥Ù¡¼¥¹(¥â¥Ç¥ê¥ó¥°¤ËPDFAMS¤ò»ÈÍÑ)¤¬¸ø³«¤µ¤ì¤Þ¤·¤¿¡£º¸Â¦¥³¥ó¥È¥í¡¼¥ë¥Ñ¥Í¥ë¤ÎEcoliPredict¥Ü¥¿¥ó¤«¤éÆþ¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£¤Ê¤ª´Êñ¤Ê¥Ç¡¼¥¿¥Ù¡¼¥¹¤ÎÀâÌÀ¤¬¡¢EcoliPredict¥È¥Ã¥×¥Ú¡¼¥¸¤Ë¤¢¤ëAbout EcoliPredict¤ò¤´Í÷¤¯¤À¤µ¤¤¡£
2008ǯ4·î11Æü ËÌΤÂç³ØÌô³ØÉô£³Ç¯À¸¤Î¡Öʬ»Ò¤ÎΩÂι½Â¤¤ÈÀ¸Ì¿¡×¤Î¹ÖµÁ¥Î¡¼¥È¤ò½ç¼¡·ÇºÜ¤·¤Þ¤¹¡£PDFAMS¤Ç¥â¥Ç¥ê¥ó¥°¤·¤¿¥¿¥ó¥Ñ¥¯¼Á¤È¥É¥é¥Ã¥°Ê£¹çÂΤΥâ¥Ç¥ë¤ÈChooseLD(Æôê2007-293751¡¢11·î12Æü½Ð´ê)¤ò»È¤Ã¤ÆÆÀ¤é¤ì¤¿¡¢¥Õ¥§¡¼¥ºII¤äIII¤ÎÌôʪ¤È¤½¤ì¤é¼õÍÆÂΤȤÎ̤ȯɽ¤Î¥É¥Ã¥­¥ó¥°Áê¸ßºîÍѹ½Â¤¤¬¼¡¡¹¤È¸ø³«¤µ¤ì¤Æ¤¤¤­¤Þ¤¹¡£º¸Â¦¤Î¥á¥Ë¥å¡¼¤«¤é¤ªÆþ¤ê¤¯¤À¤µ¤¤
2008ǯ4·î2Æü ¾¾ÌÚ¶¯¤¬¼èÄùÌò¤ò¼­Ç¤¤·¡¢ã·Æ£ÃÒ¤¬¼èÄùÌò¤Ë½¢Ç¤¤·¤Þ¤·¤¿
2008ǯ3·î21Æü "Dynamic interaction among the platform and two membrane-proiximal immunoglobulin-like domain of class I major histocompatibility complex: normal mode analysis" ¤Î¸¦µæ¤¬ Chem.Pharm.Bull.,Vol.56 No.5 (5·î¹æ)¤Îɽ»æ¤ËÁª¤Ð¤ì¤Þ¤·¤¿¡£
2008ǯ3·î14Æü JBIC((¼Ò)¥Ð¥¤¥ª»º¶È¾ðÊó²½¥³¥ó¥½-¥·¥¢¥à)¤«¤é¤ÎFAMSBASE(¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥Ç-¥¿¥Ù-¥¹)¸ø³«½ªÎ»¤Ë¤È¤â¤Ê¤¤¡¢¿Í¥²¥Î¥à¾å¤Ë¥³-¥É²½¤µ¤ì¤Æ¤¤¤ë¥¿¥ó¥Ñ¥¯¼Á¤Ë¤Ä¤¤¤ÆºÆ¥â¥Ç¥ê¥ó¥°¤·¤¿Human FAMSBASE(888,625¥â¥Ç¥ë)¤Î¾¦Éʲ½¤ò¸¡Æ¤¤·¤Æ¤ª¤ê¤Þ¤¹¡£
New Human FAMSBASE¤Ë´Ø¿´¤¬¤ªÍ­¤ê¤ÎÊý¤Ï¡¢¤ªÌ䤤¹ç¤ï¤»¥Õ¥©-¥à¤«¤é¤ªÌ䤤¹ç¤ï¤»¤¯¤À¤µ¤¤¡£
2008ǯ3·î5Æü ´ð½à¿¶Æ°²òÀÏË¡¤Ë¤è¤êClass I Major Histocompatibility Complex (MHC)ʬ»Ò¤Î»°¥É¥á¥¤¥ó¤ÎÁê¸ßºîÍÑÌò³ä¤ò²òÀϤ·¤¿ÏÀʸ¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£Chem.Pharm.Bull.,56(5),635-641 (2008) Dynamic interaction among the platform and two membrane-proiximal immunoglobulin-like domain of class I major histocompatibility complex: normal mode analysis
2008ǯ3·î1Æü ¸¶»Ò¥¿¥¤¥×¤È¸¶»Ò´Ö·ë¹çµ¬Â§¤ò´Þ¤à²½³Øµ­½Ò»Ò¤ò¥¿¡¼¥²¥Ã¥È¥¿¥ó¥Ñ¥¯¼Á¤Î£³¼¡¸µºÂɸ¤«¤éÃê½Ð¤·¤ÆºîÀ®¤µ¤ì¤¿²½¹çʪ»ØÌæ(Finger Print)¥»¥Ã¥È¤Ë¥Õ¥£¥Ã¥È¤¹¤ë²½¹çʪ¸ôÊä¤ò¥¤¥ó¥·¥ê¥³¥¹¥¯¥ê¡¼¥Ë¥ó¥°¤¹¤ëÊýË¡ChooseLD¤ò³«È¯¤·¤Þ¤·¤¿¡£Æôê2007-293751(11·î12Æü½Ð´ê); Chem.Pharm.Bull.,56(5),742-744 (2008) Bioinformatics based ligand-docking and in-silico screening
2008ǯ2·î1Æü CAPRI Round 6¡Á12¤ÎÀ®²Ì¤òProteins¤ËÅê¹Æ¤·¡¢ÏÀʸ¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿ CAPRI (the Critical Assessment of Predicted Interaction) ¤Ï¡¢¥¿¥ó¥Ñ¥¯¼Á-¥¿¥ó¥Ñ¥¯¼Á´Ö¥É¥Ã¥­¥ó¥°¹½Â¤Í½Â¬¹ñºÝ¥³¥ó¥Æ¥¹¥È¤Ç¤¹¡£
2007ǯ10·î1Æü CASP7¤ÎÀ®²Ì¤òProteins¤ËÅê¹Æ¤·¡¢ÏÀʸ¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2007ǯ9·î25Æü Þ¼¾å¶Õ»Ê¤¬Âåɽ¼èÄùÌò¤òÂàǤ¤·µ»½Ñ¸ÜÌä¤Ë¡¢¾®¾¾¹î°ìϺ¤¬Âåɽ¼èÄùÌò¤Ë½¢Ç¤¤·¤Þ¤·¤¿
2007ǯ5·î11Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¼Ò¼çºÅ¤Î¹Ö±é²ñ(Ì£¤ÎÁdzô¼°²ñ¼Ò¥é¥¤¥Õ¥µ¥¤¥¨¥ó¥¹¸¦µæ½êÎëÌÚÜÆ°ìϺÍý»ö)¤È¿ÆËÓ²ñ¤ò¶äºÂ¤«¤Í¤Þ¤Ä¥Û¡¼¥ë¤Ç¹Ô¤¤¤Þ¤·¤¿¡£
2006ǯ12·î1Æü ¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¥³¥ó¥Æ¥¹¥È(CASP7)¤ÇÀ¤³¦ºÇ¹â¥ì¥Ù¥ë¤ÎÀ®²Ì¡£¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀ¶µ¼ø¡ÊËÌΤÂç³Ø¡Ë¤¬¾·ÂÔ¹Ö±é
2006ǯ 9·î29Æü¡¡­ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤ÈÍý²½³Ø¸¦µæ½ê¤Î¶¦Æ±¸¦µæÀ®²Ì RIKEN FAMSBASE ¤Î¸ø³«¤Ë´Ø¤·¤Æ¡¢Æü·Ð¿·Ê¹¡¢Æü·Ð»º¶È¿·Ê¹¡Ê£¹ÌÌ¡Ë¡¢Æü´©¹©¶È¿·Ê¹¡Ê31ÌÌ¡Ë ¤Ë¾Ò ²ðµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2006ǯ 9·î28Æü¡¡­ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤ÈÍý²½³Ø¸¦µæ½ê¤Î¶¦Æ±¸¦µæÀ®²Ì RIKEN FAMSBASE ¤Î¸ø³«
2006ǯ 9·î7Æü¡¡Æü·Ð»º¶È¿·Ê¹¡¡1£´ÌÌ¡¡°åÎÅ¡¦¥Ð¥¤¥ª¡¡¥Ð¥¤¥ª¡Ö¤³¤ì¤Ç¹¶¤á¤ë¡×¤Ë­ê ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î¾Ò²ðµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2006ǯ 6·î19Æü ³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Ï¥¿¥«¥é¥Ð¥¤¥ª³ô¼°²ñ¼Ò¤ÈÈÎÇäÄó·È¤ò·ë¤Ó¡¢¶¦Æ±¤Ç¿·µ¬¥²¥Î¥à¾ðÊó¤ÎΩÂι½Â¤Í½Â¬¥µ¡¼¥Ó¥¹¤ò³«»Ï¤·¤Þ¤¹¡£
2006ǯ 6·î16Æü CASP7¤Ë¤ª¤¤¤Æ¡¢ËÌΤÂç³Ø¤ÎFAMS-MULTI¥Á¡¼¥à¤Î¥â¥Ç¥ë¤¬¹â¤¤É¾²Á¤ò¼õ¤±¡¢¡ÖÀºÌ©¤Ê¥â¥Ç¥ëºîÀ® (Targets Refinement)¡×¤Î¥³¥ó¥Æ¥¹¥È¤ÎÂêºà¤È¤·¤ÆÁª¤Ð¤ì¤Þ¤·¤¿¡£
2006ǯ 2·î18Æü ÆüËܷкѿ·Ê¹1Ì̤˥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹´ØÏ¢¤Îµ­»ö¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿¡£
2006ǯ 1·î20Æü Íý²½³Ø¸¦µæ½ê¤Ï¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹¤Î¥¿¥ó¥Ñ¥¯¼ÁÌóÀé6É´¼ïÎà¤Î¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥â¥Ç¥ë¤ò̵½þ¤Ç¸ø³«¤·¤Þ¤·¤¿¡£
2005ǯ 12·î16Æü ËÌΤÂç³ØÌô³ØÉô £Á½õ¶µ¼ø(Ëܿͤδõ˾¤Ë¤è¤êƿ̾µ­½Ò) ((³ô)¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹ µ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼)¤¬ 17ǯÅÙ ÆüËÜÌô³Ø²ñÌô³Ø¸¦µæ¥Ó¥¸¥ç¥óÉô²ñ¾Þ ¼õ¾Þ
2005ǯ 12·î1Æü ³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎÇß»³½¨ÌÀ¶µ¼ø¤Î¸¦µæ³è Æ°¤ò¾Ò²ð¤¹¤ëµ­»ö¤¬¡Ö¥á¥Ç¥£¥«¥ë¥É¥¥¡×»ï¤Ë·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2005ǯ 11·î22Æü¡¡SFC Entreprenuer Award 2005 Platinum Award¡Ê1°Ì¡Ë¼õ¾Þ
·Ä±þµÁ½ÎÂç³ØSFC Entrepreneur Award2004¤Ë¤Æ­ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹Âåɽ¼èÄùÌò¼ÒĹ¡¡Þ¼¾å¶Õ»Ê¤¬Platinum Award¡Ê1°Ì¡Ë¤ò¼õ¾Þ¡£SFC Entrepreneur Award¤Ï¡¢ÁÏΩ¤«¤éº£¤Þ¤Ç¿ô¿¤¯¤Îµ¯¶È²È¤òÇڽФ·¤Æ¤¤¤ëSFC¤ÎÎò»Ë¤òÇطʤˡ¢·ÄØæµÁ½ÎÂç³Ø¤È²¿¤é¤«¤Î´Ø¤ï¤ê¤ò¤â¤Ã¤Æ¤¤¤ë(¤¢¤ë¤¤¤Ï´Ø¤ï¤ê»ý¤Ä¤³¤È¤ò´õ˾¤·¤Æ¤¤¤ë)µ¯¶È²È¤òȯ·¡¤·¡¢³×¿·Åª¤Êµ»½Ñ¡¦¥Î¥¦¥Ï¥¦¤ò³èÍѤ·¤Æ¡¢¿·¤·¤¤»Ô¾ì¤ò³«Â󤹤뤳¤È¤Ë¤è¤ê¡¢¼Ò²ñŪ¤Ê¹×¸¥¤ò¼Â¸½¤·¤è¤¦¤È¤¹¤ë¡¢µ¯¶È²ÈÀº¿À°î¤ì¤ë·Ð±Ä¼Ô¤òɽ¾´¤·¤Þ¤¹¡£
2005ǯ 8·î15Æü Æü·Ð¥Ð¥¤¥ª¥Ó¥¸¥Í¥¹¡¡2005ǯ£¹·î¹æ¡Ê2005.09 p60-65¡Ë¤Ë¡¢¡Ê³ô¡Ë¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¼Ò¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿¡£
2005ǯ 4·î 7Æü ËÌΤÂç³ØÌô³ØÉôÇß»³½¨ÌÀ¶µ¼ø¡ÊÍý²½³Ø¸¦µæ½êµÒ°÷¼ç´É¸¦µæ°÷¡¢¡Ê³ô¡Ë¥¤¥ó¥·¥ê¥³¥µ¥¤ ¥¨¥ó¥¹¤Î¸¦µæ¥¢¥É¥Ð¥¤¥¶¡¼¡Ë¤¬ÊüÁ÷Âç³ØÂç³Ø±¡¡Öʪ¼Á´Ä¶­²Ê³Ø­µ¡×¤ÎÂè12²ó¡Öʬ»Ò¤ÎΩÂι½Â¤¤ÈÀ¸Ì¿¡×¤ÈÂꤷ¤Æ¹ÖµÁ¤ò¤·¤Þ¤¹¡£º£Ç¯¡¢6·î27Æü¡Ê·î¡Ë¤Î14»þȾ¤«¤éÊü±Ç¤µ ¤ì¤ëͽÄê¤Ç¤¹¡£
2005ǯ 2·î17Æü¡¡Æü·Ð»º¶È¿·Ê¹21ÌÌ¡ÖÂç³ØVB¿Í¡ÁÃΤòÀ¸¤«¤¹¡Á¡×¤Ë¡¢¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³ØÌô³ØÉô Çß»³½¨ÌÀ¶µ¼ø¤Ë´ØÏ¢¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£¤³¤Îµ­»ö¤Ç¤Ï¡¢Çß»³¶µ¼ø¤ÎÃÁÇò¼ÁΩÂι½Â¤¤Î¸¦µæ¶ÈÀӤȤ½¤³¤«¤éȯŸ¤·¤Æ³ô¼°²ñ¼Ò¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î»ö¶È²½¤Ë»ê¤Ã¤¿·Ð°Þ¤¬¾Ò²ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
2004ǯ 12·î14Æü¡¡Æü·Ð¥Ð¥¤¥ª¥Æ¥¯¤Ë¡Ö¥¤ ¥ó ¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼¤ÎËÌΤÂç³Ø£Á½õ¶µ¼ø(Ëܿͤδõ˾¤Ë¤è¤êƿ̾µ­½Ò)¾·ÂÔ¹Ö±é¡×¤Ë´ØÏ¢¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 12·î17Æü ¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬¥³¥ó¥Æ¥¹¥È¤ÇÀ¤³¦ºÇ¹â¥ì¥Ù¥ë¤ÎÀ®²Ì¡¢¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¥¢¥É¥Ð¥¤¥¶¡¼ ËÌΤÂç³Ø£Á½õ¶µ¼ø(Ëܿͤδõ˾¤Ë¤è¤êƿ̾µ­½Ò)¾·ÂÔ¹Ö±é
2004ǯ 10·î 4Æü¡¡Ìî¼ëú·ô¤Î½µÊó ¡ÖÅ·´ã¶À¡×¡Ê10·î4Æü¹æ¡Ë¤Ë¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î»ö¶È¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 9·î27Æü ÆüËܷкѿ·Ê¹¤Ë¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤¥Ç-¥¿¥Ù-¥¹³«È¯(À¤³¦ºÇÂç)¤Ë´Ø¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 9·î 4Æü ÆüËܷкѿ·Ê¹¤ËSARS¼£ÎÅÌô¸ôÊä²½¹çʪȯ¸«¤Ë´Ø¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 6·î25Æü »°°æʪ»º³ô¼°²ñ¼Ò¤È¤Î·ÀÌóÄù·ë¤Ë¤Ä¤¤¤Æ
2004ǯ 6·î25Æü ÆüËܷкѿ·Ê¹(ͼ´©)£³Ì̤˥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤È»°°æʪ»º´ØÏ¢¤ÎÄó·È¤Ë´Ø¤¹¤ëµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿¡£
2004ǯ 6·î 1Æü ¿·À½ÉʤÎȯÇä¤Î¤ªÃΤ餻¡£Éý¹­¤¤°åÌô¡¦À¸Ì¿²Ê³Ø¤Î¸¦µæ¼Ô¤ËÀ¤³¦ºÇ¹âÀºÅÙ¤ÎÃÁÇò¼ÁΩÂι½Â¤Í½Â¬¥½¥Õ¥È¤ò¼ê·Ú¤Ë»È¤Ã¤Æ¤¤¤¿¤À¤¯¤¿¤á¤Ë¡¢PDFAMS Pro ¤Ë Web User Interface µ¡Ç½¤òÅëºÜ¤·¤¿ PDFAMS Pro+ ÈÎÇä¤ò³«»Ï¤·¤Þ¤¹¡£
2004ǯ 3·î10Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¤Î¡Ö¥²¥Î¥àÁÏÌô»Ù±ç¥·¥¹¥Æ¥à¤Î³«È¯¡×¥×¥í¥¸¥§¥¯¥È¤ÏÊ¿À®15ǯÅÙ¡Ö¸ø±×¿®Â÷¤ß¤º¤Û¥Ë¥å¡¼¥Ó¥¸¥Í¥¹°éÀ®´ð¶â¡×½õÀ®Àè9·ï¤ËÁª¤Ð¤ì ¤Þ¤·¤¿¡ÊÁí±þÊç¿ô210·ï¡Ë¡£ ( Æü´©¹©¶È¿·Ê¹¼Ò 2004ǯ3·î5Æü 21ÌÌ )
2004ǯ 3·î 1Æü Ä»¥¤¥ó¥Õ¥ë¥¨¥ó¥¶¥¦¥¤¥ë¥¹ Neuraminidase ¥â¥Ç¥ë²èÁü¤ò¸ø³«¤·¤Þ¤·¤¿
2004ǯ 1·î23Æü ÆüËܷкѿ·Ê¹17Ì̤˥³¥ó¥Ô¥å¡¼¥¿¡¼¥·¥ß¥å¥ì¡¼¥·¥ç¥ó´ØÏ¢¤Îµ­»ö¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 12·î25Æü Æü·Ð»º¶È¿·Ê¹1Ì̤ËPDFAMS´ØÏ¢¤Îµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2003ǯ 12·î 8Æü PDFAMS´ØÏ¢¤ÎÆüËÜSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 10·î29Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤ÎNEWGPCR¥Ç¡¼¥¿¥Ù¡¼¥¹¤Ë³èÀ­·¿GPCR¥Ç¡¼¥¿¤òÄɲÃ
2003ǯ 10·î4Æü NHK¶µ°é¥Æ¥ì¥Ó¡ÖETV¥é¥¤¥Ö¥é¥ê¡¼¡×¡ÊºÆÊüÁ÷¡§10·î3Æü¶âÍËÆü¿¼Ìë2:15¡ÁÊüÁ÷ʬ¡Ë¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 10·î2Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤ËNEWGPCR¥Ç¡¼¥¿¥Ù¡¼¥¹¤òÄɲÃ
2003ǯ 9·î10Æü À¾¥Ê¥¤¥ë¥¦¥¤¥ë¥¹Áý¿£´ØÏ¢ÃÁÇò¼Á¥â¥Ç¥ë²èÁü¤ò¸ø³«¤·¤Þ¤·¤¿
2003ǯ 9·î 9Æü NHK¥Ë¥å¡¼¥¹10(9·î9Æü22»þ¡Á)¤Ç½Å¾ÉµÞÀ­¸ÆµÛ´ï¾É¸õ·²¡ÊSARS)¤Î´µ¼Ô¤¬¥·¥ó¥¬¥Ý¡¼¥ë¤ÇȯÀ¸¤·¤¿¤È¤Î¥Ë¥å¡¼¥¹¤¬Êü±Ç¤µ¤ì¤Þ¤·¤¿
2003ǯ 9·î 9Æü NHK¥Ë¥å¡¼¥¹10(9·î9Æü22»þ¡Á)¤ÇSARS¥×¥í¥Æ¥¢¡¼¥¼¤Ë·ë¹ç¤¹¤ë°åÌôÉʤª¤è¤Ó¥ê¥¬¥ó¥É´ØÏ¢¤Î¥Ë¥å¡¼¥¹¤¬Êü±Ç¤µ¤ì¤Þ¤·¤¿
2003ǯ 9·î 9Æü NHK¥Ë¥å¡¼¥¹(9·î9Æü7»þ¡Á)¤Ç°¦É²Âç³Ø¤Ë¤Æ¾®Çþæõ²ê¤ò»È¤Ã¤Æ¥»¥ë¥Õ¥ê¡¼¤Î¾õÂÖ¤ÇSARS¥×¥í¥Æ¥¢¡¼¥¼¤ò¿Í¹©¹çÀ®¤¹¤ë¤³¤È¤ËÀ®¸ù¤Î¥Ë¥å¡¼¥¹¤¬Êü±Ç¤µ¤ì¤Þ¤·¤¿
2003ǯ 9·î 6Æü SARS¥×¥í¥Æ¥¢¡¼¥¼¤Ë·ë¹ç¤¹¤ë°åÌôÉʤª¤è¤Ó¥ê¥¬¥ó¥É¥é¥ó¥­¥ó¥°É½¤ò¸ø³«¤·¤Þ¤·¤¿
2003ǯ 9·î 2Æü ÆüËܷкѿ·Ê¹¤ËSARS¿·Ìô´ØÏ¢µ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2003ǯ 8·î31Æü ¿ÀÆàÀʹ¤ËËÌΤÂç³ØÇß»³½¨ÌÀ¶µ¼ø¡Ê¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹µ»½Ñ¥¢¥É¥Ð¥¤¥¶¡¼¡Ë¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 8·î19Æü ¥Ú¥×¥Á¥ÉÇÛÎ󤫤é¤Î¹½Â¤¸¡º÷¥µ¡¼¥Ó¥¹¤ò³«»Ï¤·¤Þ¤·¤¿
2003ǯ 7·î26Æü PDB(Protein Data Bank)¤Ë¤ÆXÀþ²òÀϤˤè¤ëSARS¹½Â¤¥Ç¡¼¥¿¤¬¸ø³«¤µ¤ì¤Þ¤·¤¿
2003ǯ 7·î25Æü NHK¶µ°é¥Æ¥ì¥Ó¥µ¥¤¥¨¥ó¥¹ZERO¡ÊÁí½¸ÊÔ¡§7·î29Æü²ÐÍËÆü¿¼Ìë0»þ¡ÁÊüÁ÷ʬ¡Ë¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 7·î23Æü ¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Í­½þÄ󶡥µ¡¼¥Ó¥¹¤ò³«»Ï¤¤¤¿¤·¤Þ¤·¤¿
2003ǯ 7·î18Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤Ë´Ø¤¹¤ëÆüËÜSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 7·î18Æü JBICFAMSBASE¥µ¡¼¥Ó¥¹¤ËGPCR¥Ç¡¼¥¿¥Ù¡¼¥¹¤òÄɲÃ
2003ǯ 7·î17Æü SARS Proteinase¥â¥Ç¥ë¤ËHIV¥×¥í¥Æ¥¢¡¼¥¼Á˳²ºÞNelfinavir¡Ê1OHR¡Ë¤ò¥É¥Ã¥­¥ó¥°¤·¤¿¥â¥Ç¥ë¹½Â¤¤Î¸ø³«³«»Ï
2003ǯ 7·î15Æü Åìµþ°å²Ê»õ²ÊÂç¤ÈµþÅÔÂç¤Ê¤É¤Î¥°¥ë¡¼¥×¡¢¥¨¥¤¥º¤Î¼£ÎÅÌôNelfinavir¤¬SARSÍÞÀ©¸ú²Ì¤¬¤¢¤ë¤³¤È¤òȯɽ
2003ǯ 6·î17Æü NHK¶µ°é¥Æ¥ì¥Ó¥µ¥¤¥¨¥ó¥¹ZERO¡ÊSARSÆý¸¡§7·î8Æü²ÐÍËÆü¿¼Ìë0»þ¡ÁÊüÁ÷ʬ¡Ë¤ÇËÌΤÂç³ØÇß»³¸¦µæ¼¼¤¬¾Ò²ð¤µ¤ì¤Þ¤·¤¿
2003ǯ 6·î15Æü Æü·Ð¥Ð¥¤¥ª¥Ó¥¸¥Í¥¹7·î¹æ¤ËSARS¥¿¥ó¥Ñ¥¯¼ÁΩÂι½Â¤Í½Â¬´ØÏ¢¤Îµ­»ö¤¬·ÇºÜ¤µ¤ì¤Þ¤·¤¿
2003ǯ 6·î11Æü SARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Ìµ½þÄ󶡥µ¡¼¥Ó¥¹¤Ë´Ø¤¹¤ëÊƹñSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 6·î 4Æü JBiC¤ÎWeb¥µ¥¤¥È¤Ë¤ª¤¤¤ÆFAMSBASE¤ÎÄ󶡤ò³«»Ï
2003ǯ 5·î30Æü ¥«¥Ê¥ÀNew BrunswickÂç³Ø¡¢Í½Â¬¤·¤¿SARS¥¦¥¤¥ë¥¹Protease¹½Â¤¤ò¸ø³«
2003ǯ 5·î18Æü Ãæ¹ñ¥°¥ë¡¼¥×¡¢SARS¥³¥í¥Ê¥¦¥¤¥ë¥¹Protease¹½Â¤¤È¥Ç¥¶¥¤¥ó¤·¤¿Á˳²ºÞ¤ò¸ø³«
2003ǯ 5·î16Æü Eidogen¼Ò¡¢SARS¥¦¥¤¥ë¥¹¤ÎÃÁÇò¼Áʬ²ò¹ÚÁǤÎΩÂι½Â¤¤ò¸øŪ¥Ç¡¼¥¿¥Ð¥ó¥¯¤Ë´óÂ÷
2003ǯ 5·î13Æü ÆÈ¥°¥ë¡¼¥×¡¢SARS protease¤Î¹½Â¤¤òÊÆ¥µ¥¤¥¨¥ó¥¹¡ÊÅÅ»ÒÈǡˤËȯɽ
2003ǯ 5·î12Æü SARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Ìµ½þÄ󶡥µ¡¼¥Ó¥¹¤Ë´Ø¤¹¤ëÆüËÜSGIȯ¥×¥ì¥¹¥ê¥ê¡¼¥¹
2003ǯ 5·î 9Æü SARS¥¿¥ó¥Ñ¥¯¼Á¹½Â¤Ìµ½þÄ󶡥µ¡¼¥Ó¥¹¤ò³«»Ï
2002ǯ11·î26Æü ¥¤¥ó¥·¥ê¥³¥µ¥¤¥¨¥ó¥¹¼ÒÀßΩ


Copyright (C) 2003 In-Silico Sciences Inc. All Rights Reserved